Document:

Exhibit 4.14

AMYRIS, INC.

PROMISSORY NOTE 

	$8,500,000	 	                            Issuance date: June 11, 2019

    

Amyris,
Inc., a Delaware corporation (the “Company”), for value received, hereby promises to pay to FORIS
VENTURES, LLC, or registered assigns (the “Holder”), the principal sum of Eight Million Five Hundred Thousand
Dollars ($8,500,000), or such lesser amount as shall then equal the outstanding principal amount hereunder, on the earlier of (i)
the business day immediately following the date that the Company provides written notice to the Holder that DSM International B.V.
(“DSM”) has exercised all of its common stock purchase warrants issued by the Company to DSM on May 11, 2017
and August 7, 2017 and that currently have an exercise price of $2.87 per share (the “DSM Warrants”) and (ii)
August 28, 2019 (the “Maturity Date”) and to pay interest thereon, from the date of this Note, or from the most
recent date to which interest has been paid on this Note, at the rate of twelve and one-half percent (12.5%) per annum (calculated
on a simple interest basis) until the Maturity Date or the earlier repayment or other satisfaction of this Note.

Payment
of the principal of this Note shall be made upon the surrender of this Note to the Company at its chief executive office (or such
other office within the United States as shall be designated by the Company to the holder hereof) (the “Designated Office”)
on the Maturity Date or such earlier date in accordance with the terms of this Note. All amounts payable in cash with respect to
this Note shall be made by wire transfer to the holder, provided that if the holder shall not have furnished wire
instructions in writing to the Company no later than the business day immediately prior to the date on which the Company makes
such payment, such payment may be made by U.S. dollar check mailed to the address of the holder as such address shall appear in
the Company register. Notwithstanding anything contained herein or in that certain common stock purchase warrant issued by the
Company to the Holder on April 16, 2019 (the “April 16 Warrant”) to the contrary, provided that DSM has exercised
in full all of the DSM Warrants, the Holder shall be permitted, upon written notice to the Company, to pay the exercise price for
any shares of the Company’s common stock, par value $0.0001 per share, issuable upon exercise of the April 16 Warrant (the
“Warrant Shares”) by surrendering to the Company all, or any portion, of this Note and all or such portion of
the outstanding amounts due pursuant to this Note, as applicable, shall be cancelled in exchange for the payment of the exercise
price for such Warrant Shares and, if the Holder surrenders less than all of this Note, the Company shall promptly thereafter issue
to the Holder a new promissory note for the remaining amounts under this Note.

This Note was
issued pursuant to the Credit Agreement, dated as of June 11, 2019 (as amended from time to time, the “Agreement”),
by and among the Company, the original holder of this Note and is subject to provisions of the Agreement. Capitalized terms used
but not otherwise defined herein shall have the meaning given to such terms in the Agreement.

1.  Redemption.  This
Note is subject to redemption, in whole or from time to time in part (in any amount that is an integral multiple of $1,000), upon
not less than five (5) days’ prior written notice in the manner provided in Section 4(b) hereof, at the election of the Company,
at a redemption price of 100% of the amount hereof, together with accrued and unpaid interest to, but excluding, the redemption
date.

2.  Certain Covenants. Until the Obligations
hereunder are paid or otherwise satisfied in full:

     

     

    
		(a)	The Company will maintain or cause to be maintained its corporate or other organizational existence
and good standing in its jurisdiction of incorporation and maintain its qualification in each jurisdiction where the failure to
so qualify would reasonably be expected to have a Material Adverse Effect.

		(b)	The Company will comply with all applicable statutes, regulation and orders of, and all applicable
restrictions imposed by, all governmental bodies, domestic or foreign, in respect of the conduct of its business and the ownership
of its property, other than those the noncompliance with which would not have, and which would not reasonably be expected to have,
a Material Adverse Effect.

		(c)	The Company will cause the proceeds of the loans evidenced under this Note to be used solely (a)
as working capital and (b) to fund the Company’s general business requirements, and not for personal, family or household
purposes.

		(d)	The Company will execute any further instruments and take any further action as the Holder reasonably
requests to effect the purposes of this Note or the Agreement.

    3.  Events of Default.  

		(a)	“Event of Default”, wherever used herein, means any one of the following events (whatever the reason for
such Event of Default and whether it shall be voluntary or involuntary or be effected by operation of law or pursuant to any judgment,
decree or order of any court or any order, rule or regulation of any administrative or governmental body):

		(i)	default in the payment of any amount upon this Note when it becomes due and payable;

		(ii)	default in the performance, or breach, of any covenant of the Company herein (other than a default in the performance or breach
of which is specifically dealt with elsewhere in this Section 3(a)) and continuance of such default or breach for a period of 10
days;

		(iii)	the commencement against the Company of an involuntary case or proceeding under any applicable federal or state bankruptcy,
insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated bankrupt or insolvent and
such case or proceeding is not dismissed or stayed within 45 days;

		(iv)	the commencement by the Company of a voluntary case or proceeding under any applicable federal
or state bankruptcy, insolvency, reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt
or insolvent, or the consent by the Company to the entry of a decree or order for relief in respect of the Company in an involuntary
case or proceeding under any applicable federal or state bankruptcy, insolvency, reorganization or other similar law or to the
commencement of any bankruptcy or insolvency case or proceeding against either the Company, or the filing by either the Company
of a petition or answer or consent seeking reorganization or similar relief under any applicable Federal or state law, or the consent
by it to the filing of such petition or to the appointment of or taking possession by a custodian, receiver, liquidator, assignee,
trustee, sequestrator or other similar official of the Company or of any substantial part of its property, or the making by either
the Company of an assignment for the benefit of creditors, or the admission by either the Company in writing of its inability to
pay its debts generally as they become due, or the taking of corporate action by the Company in furtherance of any such action;

     

     

    
		(v)	The Company or any Person acting for the Company makes any representation, warranty, or other statement
now or later in this Note or the Agreement or in any writing delivered to the Holder or to induce the Holder in connection with
this Note, the Agreement or any other document entered into in connection with this Note or the Agreement or to enter this Note,
the Agreement or any other document entered into in connection with this Note or the Agreement, and such representation, warranty,
or other statement is incorrect in any material respect when made; or

		(vi)	at any time, any “person” or “group” (as such terms are used in Sections
13(d) and 14(d) of the Exchange Act), shall become, or obtain rights (whether by means of warrants, options or otherwise) to become,
the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act), directly or indirectly, of
fifty percent (50.0%) or more of the ordinary voting power for the election of directors of the Company (determined on a fully
diluted basis).

		(b)	Upon the occurrence and during the continuance of an Event of Default, the Holder may (a) declare
all Obligations hereunder immediately due and payable (but if an Event of Default described in Section 3(a)(iv) or 3(a)(v) occurs
all Obligations hereunder are immediately due and payable without any action by the Holder) and (b) exercise all rights and remedies
available to the Holder under this Note, the Agreement or at law or equity. The Company will give the Holder notice, within five
(5) business days of the occurrence thereof, of any Event of Default of which it is or becomes aware. Such notice shall be given
in the manner provided in Section 4(b).

4.  Other.  

 

		(a)	No provision of this Note shall alter or impair the obligation of the Company, which is absolute
and unconditional, to pay the principal of and interest on this Note at the times and places herein prescribed or to repay or otherwise
satisfy this Note as herein provided.

		(b)	The Company will give prompt written notice to the Holder of any change in the location of the
Designated Office. Any notice to the Company or to the Holder shall be given in the manner set forth in the Agreement.

     

     

    
		(c)	The transfer of this Note is registrable on the register maintained by the Company upon surrender
of this Note for registration of transfer at the Designated Office, duly endorsed by, or accompanied by a written instrument of
transfer in form satisfactory to the Company duly executed by, the holder hereof or such holder’s attorney duly authorized
in writing, and thereupon one or more new Securities, of authorized denominations and for the same aggregate principal amount,
will be issued to the designated transferee or transferees. Such securities are issuable only in registered form without coupons
in denominations of $1,000 and any integral multiple thereof. No service charge shall be made for any such registration of transfer,
but the Company may require payment of a sum sufficient to recover any tax or other governmental charge payable in connection therewith.
Prior to due presentation of this Note for registration of transfer, the Company and any agent of the Company may treat the Person
in whose name this Note is registered as the owner thereof for all purposes, whether or not this Note be overdue, and neither the
Company nor any such agent shall be affected by notice to the contrary.

		(d)	This Note shall be governed by and construed in accordance with the internal laws of the State
of California, without regard to the conflicts of law provisions of the State of California.

[The remainder of this page is intentionally
left blank]

   

 

 

 

     

     

    

IN WITNESS WHEREOF, the Company
has caused this Note to be duly executed.

Dated: June 11, 2019

	 	Amyris, Inc.
	 	

By:	 	

/s/ Kathleen Valiasek
	 	Name:	 	Kathleen Valiasek
	 	Title:	 	Chief Business OfficerExhibit
        10.01

         

        Confidential

 

Execution Version

 

IN ACCORDANCE
WITH ITEM 601(b)(10)(iv) OF REGULATION S-K, CERTAIN CONFIDENTIAL INFORMATION HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS
BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. THE CONFIDENTIAL INFORMATION IS DENOTED
HEREIN BY [*].

AMENDMENT NO. 2 TO

SUPPLY AGREEMENT

This Amendment No. 2 to the Supply Agreement (this “Amendment”)
is entered into as of April 16, 2019, between DSM Nutritional Products AG, Wurmisweg 576, 4303 Kaiseraugst, Switzerland, (hereinafter
"DSM”) and Amyris, Inc., 5885 Hollis Street, Emeryville, CA 94608, USA (hereinafter “Amyris”)
(each of DSM and Amyris hereinafter referred to as a “Party”, together referred to as the “Parties”).

WHEREAS, Amyris entered into a Supply Agreement, dated as of December
28, 2017, with DSM Produtos Nutricionais Brasil S.A. (the “Agreement”);

WHEREAS, On January 12, 2018, DSM’s affiliate DSM Produtos
Nutricionais Brasil S.A. assigned all of its rights, title and interest in the Agreement to DSM;

WHEREAS, On November 19, 2018 the Parties entered into Amendment
No. 1 to the Agreement;

WHEREAS, the Parties desire to further amend the Agreement; and

NOW, THEREFORE, in consideration of the mutual promises contained
herein, and for other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the Parties
agree as follows:

		1.	Amendments.

		a.	Section 1.9 of the Agreement is hereby deleted and amended and restated to read:

“[Reserved]”

		b.	Section 2.3 of the Agreement is hereby amended and restated (solely to remove the reference therein to the “Novvi Contract”)
and shall read in its entirety as follows:

“Upon the Effective Date, Amyris will provide to DSM a product forecast
for the calendar year 2018 (each, a “Product Forecast”). Thereafter, by the fifteenth (15th) business day of the first
month of each new quarter, Amyris will provide to DSM a rolling quarterly forecast that consists of four (4) calendar quarters
for any Product, which notice shall indicate the Product and the desired volume and completion date, together with any other information
reasonably necessary for DSM to carry out such production. DSM shall carry out the Services in accordance with each such notice
by Amyris (i) so long as the forecast (i) does not exceed the capacity of the Facility; (ii) change is provided more than ninety
(90) days in advance and; (iii) subject to DSM’s obligations to honor the terms of the Vitamin E Contract. Furthermore, DSM
will use reasonable efforts to deliver on any changes to the production forecast that are provided by Amyris less than ninety (90)
days in advance. It is agreed by the Parties, however, that (i) where DSM is not reasonably able to decrease production with less
than ninety (90) days’ prior notice, Amyris will be bound to purchase the original amount it projected for such period, and
(ii) where DSM is not reasonably able to increase production with less than ninety (90) days’ prior notice, it shall not
be required to provide to Amyris more than the original amount of Product(s) Amyris projected for such period. It is further agreed
that Amyris shall be required to purchase all quantities of Non-Farnesene Products that DSM may produce for Amyris in response
to a Product Forecast from Amyris. Amyris shall provide DSM with Product Strain(s) in amounts reasonably required to carry out
such Services, as well as the then-current version of applicable Amyris Protocols.”

     

     

    
 

Confidential

 

		c.	Section 8.1(a) of the Agreement is hereby amended and restated (solely to remove
the reference therein to the “Novvi Contract”) and shall read in its entirety as follows:

“with respect to Non-Farnesene Products, until the date Amyris determines that
the Amyris’s Brotas 2 facility is fully operational and meets its production targets, but in any event (i) no later than
December 31, 2021, and (ii) subject to DSM’s obligations to honor the terms of the Vitamin E Contract; and”

 

		d.	Annex 4 of the Agreement is hereby amended and restated to read in its entirety as set forth in Amended and Restated Annex
4 attached hereto.

		2.	Effective Date. This Amendment shall become effective as of the date that Amyris receives the Cash Payment in accordance
with that certain letter agreement dated April 16, 2019 between DSM and Amyris regarding the Assignment of Value Sharing Agreement.

		3.	No Other Amendments. Except as expressly amended hereby, the terms and conditions of the Agreement shall remain unchanged
and in full force and effect, and the execution of this Amendment is not a waiver by either Party of any of the terms or provisions
of the Agreement. In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of
this Amendment shall govern. Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same
meanings as such terms are given in the Agreement. For clarity, any cross-references to Agreement Sections refer to those Agreement
Sections as amended by this Amendment.

		4.	Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed and original,
but all of which together shall constitute one and the same document.

[Remainder
of Page Intentionally Left Blank.]

 

 

 

 

 

     

     

    

Confidential

IN WITNESS WHEREOF, DSM and Amyris have caused this Amendment
to be executed as of the date first written above by their respective officers thereunto duly authorized.

 

DSM NUTRITIONAL PRODUCTS AG

		By:	/s/ Benedikt Suter

Name: Benedikt Suter

Function: General Counsel

		By:	/s/ Bruno Mueller

Name: Bruno Mueller

Function: Vice-President

AMYRIS, INC.

		By:	/s/ John Melo

Name: John Melo

Title: President & CEO

 

     

     

    

Confidential

 

Amended and Restated Annex 4

Manufacturing Fee

 

[*]

 

 

 

[*] Certain portions denoted
with an asterisk have been omitted.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]